Extracellular Volume Fraction Calculated Using Contrast-Enhanced Computed Tomography as a Biomarker of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: A Preliminary Histopathological Analysis

Table 1

Patient demographics.

Characteristic	Value
Total number of patients	26
Sex
Male	17 (65.4%)
Female	9 (34.6%)
Age (year)	62.1 ± 11.2
Body mass index (kg/m^2)	23.2 ± 5.2
Site of primary lesion
Colon	20 (76.9%)
Rectum	6 (23.1%)
Chemotherapeutic regimen
FOLFOX or CapeOX	10 (38.5%)
FOLFOX or CapeOX + BV	11 (42.3%)
FOLFOX + PV	3 (11.5%)
FOLFOXIRI + BV	2 (7.7%)
Cycle of OX-based chemotherapy	9.5 ± 6.4
Purpose of chemotherapy
Neoadjuvant therapy	16 (61.5%)
Inoperative, converted to surgery	10 (38.5%)

BV, bevacizumab; OX, oxaliplatin; PV, panitumumab.